Home
This Title All WIREs
WIREs RSS Feed
How to cite this WIREs title:
WIREs Nanomed Nanobiotechnol
Impact Factor: 6.14

Bioresponsive polymers for the delivery of therapeutic nucleic acids

Full article on Wiley Online Library:   HTML PDF

Can't access this content? Tell your librarian.

Abstract Polymers present an interesting option for the delivery of genes and other therapeutic nucleic acids. In the delivery process, the polymeric carriers face many different delivery tasks and different physiological microenvironments. Polymers can be designed to respond to microenvironmental differences with changes in their physio‐chemical properties, enabling them to perform individual delivery tasks. Cleavage of covalent bonds, disassembly of noncovalent interactions, changes of protonation, conformation, or hydrophilicity/lipophilicity, can trigger such dynamic physicochemical adjustments. The polymeric carrier has to stably bind the therapeutic nucleic acid during the extracellular delivery phase and protect it against degradation in the bloodstream. At the intracellular site of action, the polyplex has to disassemble to an extent that the nucleic acid is functionally accessible. Polyplexes need to be shielded in the circulation and be inert against numerous possible biological interactions, but should actively interact with the target cell surface by electrostatic or ligand receptor interactions. Lipid‐membrane destabilization at the cell membrane or nontarget sites is usually associated with undesired cytotoxicity, the analogous biophysical event, however, is required within an endocytic vesicle for polyplex transfer into the cytosol. Strategies will be presented how bioresponsive polymers can be designed and incorporated into polyplexes. Examples include dynamic stabilization of the polymer/nucleic acid core and transient activation of properties required for crossing lipid‐membrane barriers. Bioresponsive delivery domains at the polyplex surface required for shielding, deshielding, and cell targeting also contribute to better performance. WIREs Nanomed Nanobiotechnol 2011 3 33–46 DOI: 10.1002/wnan.97 This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

This WIREs title offers downloadable PowerPoint presentations of figures for non-profit, educational use, provided the content is not modified and full credit is given to the author and publication.

Download a PowerPoint presentation of all images


Uptake processes of therapeutic nucleic acids (displayed for plasmid DNA and small interfering RNA) mediated by bioresponsive polymers.

[ Normal View | Magnified View ]

Polymers can be PEGylated through enzymatic cleavable linkers, acid labile linkers, or ionic interactions. DePEGylation of enzymatic cleavable linkers may take place in the microenvironment of the tumor, while acid labile linkages or ionic binding of PEGylated polymers may be reversed in the endosomes.

[ Normal View | Magnified View ]

Endosomal escape mediated by (a) the proton sponge effect; (b) peptides changing their conformation; (c) endosomolytic peptides masked in a pH‐labile fashion; and (d) polymers containing PEGylated endosomolytic domains.

[ Normal View | Magnified View ]

Positively charged polymers complex therapeutic nucleic acids by electrostatic interactions. Caging can stabilize the binding. Small interfering RNA and oligonucleotides can also be covalently bound to the carrier. Inside the cell polymers or covalent linkages may degrade or release their cargo by other interactions mentioned in the text.

[ Normal View | Magnified View ]

Browse by Topic

Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

The latest WIREs articles in your inbox

Sign Up for Article Alerts